About Mitochondrial genome maintenance exonuclease 1
Mitochondrial genome maintenance exonuclease 1 (MGME1) is a protein
from Homo sapiens identified by UniProt accession
Q9BQP7, 344 residues long.
MolForge cross-references it against 0 known binders and
137 disease associations.
Target properties
| Protein name | Mitochondrial genome maintenance exonuclease 1 |
| UniProt accession | Q9BQP7 |
| Gene | MGME1 |
| Organism | Homo sapiens |
| Length | 344 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (137)
Diseases linked to this target (Open Targets).
- mitochondrial DNA depletion syndrome 11 · score 0.71
- Progressive external ophthalmoplegia - myopathy - emaciation · score 0.46
- mitochondrial disease · score 0.37
- mean corpuscular hemoglobin · score 0.37
- erythrocyte count · score 0.31
- low density lipoprotein cholesterol measurement · score 0.29
- mitochondrial DNA measurement · score 0.27
- total cholesterol measurement · score 0.27
- sex hormone-binding globulin measurement · score 0.26
- bilirubin measurement · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BQP7-F1 | alphafold | PREDICTED | 75.55 | — |
Amino-acid sequence (344 residues)
MKMKLFQTIC RQLRSSKFSV ESAALVAFST SSYSCGRKKK VNPYEEVDQE KYSNLVQSVL SSRGVAQTPG SVEEDALLCG PVSKHKLPNQ GEDRRVPQNW FPIFNPERSD KPNASDPSVP LKIPLQRNVI PSVTRVLQQT MTKQQVFLLE RWKQRMILEL GEDGFKEYTS NVFLQGKRFH EALESILSPQ ETLKERDENL LKSGYIESVQ HILKDVSGVR ALESAVQHET LNYIGLLDCV AEYQGKLCVI DWKTSEKPKP FIQSTFDNPL QVVAYMGAMN HDTNYSFQVQ CGLIVVAYKD GSPAHPHFMD AELCSQYWTK WLLRLEEYTE KKKNQNIQKP EYSE
Explore Mitochondrial genome maintenance exonuclease 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets